al revenues for the Proton Therapy 
and Other Accelerators segment of EUR 
366.4 million representing an increase of 
18.65% from 2022 (2022: 308.8 EUR 
million): the revenue of Proton Therapy activities 
amounts to EUR 229.1 million (2022: EUR 218.8 million), showing a slow 
increase of 4.7% due to a slow backlog 
conversion in H1 as well as significant 
costs at completion increases following 
a high inflation; the revenue of Other Accelerators 
activities amounts to EUR 133.7 million 
(2022: